secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001607062-22-000495
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method
--------------------------------------------------------------------------------

- KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.
- Patent covers methods, means and compositions for enhancing antitumor activity of CAR T cells through dedifferentiation.
- CAR T cells are modified immune T cells that attack cancer-specific antigens; developed from bone marrow stem cells.
- Provisional application marks initial step in securing IP for this cancer treatment approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/0001607062-22-000495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/rgbp080922form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-22-000495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer